Halozyme Therapeutics, Inc.

Halozyme does not set end‑product prices; pricing power is indirect through royalty rate structures, license fees, and milestones. Its leverage stems from partners’ willingness to pay to unlock faster administration and clinic efficiency.

The newly validated EU patent preserves original royalty rates on Darzalex SC through March 2029, signaling some pricing durability. As more products launch and move outside infusion centers, the platform’s value to partners can support favorable economics in new licenses.